HitGen Inc.

HitGen Inc. is a biopharmaceutical company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. Established in 2012, the company is dedicated to the discovery and optimization of small molecules and nucleic acid drugs. HitGen focuses on building an internationally leading drug discovery and optimization system, with a strong emphasis on DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). The company offers new molecular entities at various stages of research and development for the pharmaceutical industry through diverse business models, including research and development services, out-licensing of projects, and new drug launches. It currently has approximately 20 in-house drug discovery projects at different stages, with 4 having obtained IND approvals and entered clinical trials. HitGen collaborates with pharmaceutical, biotech, and chemical companies, as well as foundations and research institutes across the Americas, Asia, Europe, Africa, and Oceania. As a pioneer in the field of DEL technology, HitGen has been committed to the development, application, and improvement of DEL technology since its establishment in 2012. For further information, please contact +86-28-85197385 or +1-508-840-9646, or visit www.hitgen.com. For business development inquiries, email [email protected].